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Abstract Pathologic staging of oncologic specimens includes the identification of the accurate lymph node status. Retrieving
more lymph nodes leads to a more reliable N0 status in the TNM classification. The aim of this prospective study was to evaluate
whether more lymph nodes can be retrieved from oncologic resection specimens when more time is invested in the search and if
this contributes to a more reliable N-status in the individual patient. A total of 67 gastrointestinal oncologic specimens were
reexamined for additional lymph nodes. The mean number of lymph nodes collected in the prospective group was compared
against two retrospective groups, one before minima for lymph node counts were set (retrospective group 1) and one after
(retrospective group 2). More lymph nodes were dissected per specimen in the prospective group (24.1 lymph nodes), compared
to the retrospective group (14.3 lymph nodes, P=<0.001). During the study period, more patients were diagnosed as pN+
compared to the two retrospective groups (62.7 vs. 47.8 % respectively, P=0.082). Significantly more lymph nodes can be
found in oncologic specimens when more time is invested in the search. This will result in more accurate staging of the tumor.
Keywords Lymph node count . Staging . Oncologic
resections . TNM classification
Introduction
Accurate pathologic staging of oncologic specimens includes
the identification of lymph node metastases. Retrieving more
lymph nodes leads to a more reliable N status, especially the
pN0 status in the TNM classification, thereby improving the
accuracy of 5-year prognosis.1
–3Moreover, the finding of even
a single lymph node metastasis has, in some tumor types,
major implications for adjuvant therapy.
Concerning the number of lymph nodes that should be
evaluated, oncologic guidelines like the American Joint
Committee on Cancer (AJCC, www.cancerstaging.org)
suggest more than 12 lymph nodes dissected per colorectal
specimen and more than 15 lymph nodes for gastric
cancer.2
–6 There are no guidelines with cutoff values for the
extent of lymphadenectomy regarding esophagectomy or
pancreaduodenectomy (Whipple) specimens.
Several studies have shown that if more lymph nodes are
found in a pT1–3N0M0 cancer patient, it will lead to a longer
5-year survival rate. This is reported for several types of can-
cer, like esophageal, stomach, colon, and rectal cancer.3
–7 The
most likely explanation for the observed association between
increased number of negative lymph nodes and improved sur-
vival is incorrect staging of patients with missed positive
lymph nodes due to the low total number of investigated
lymph nodes. So, the reliability of the pN0 status will increase
when more node negative lymph nodes are found.5
–11
An extended lymphadenectomy not only includes the en-
larged lymph nodes. It is well known that severely enlarged
lymph nodes, especially the nodes that have lost their ellipsoid
contour, often contain tumor. However, lymph node metasta-
ses are not only found in large lymph nodes. In fact, several
studies have shown that more than half of the retrieved lymph
nodes containing tumor deposits are smaller than 5 mm.12
–15
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Variables that may influence lymph node retrieval are po-
tentially related to the patient, the surgeon, the pathologist,
and neo-adjuvant regimens. Several studies have tried to in-
vestigate these variables in more detail. Literature suggests
that the largest variation in the number of lymph nodes re-
trieved in surgical specimens is accounted for by differences
between pathologists and not between surgeons.16
–20 Still,
there is an ongoing discussion between both, especially when
small numbers of lymph nodes are encountered. The surgeon
may feel that there are more lymph nodes to be found in the
surgical specimen, while the pathologists may state that the
surgeon’s resection was not complete enough.
In an attempt to shed light on this discussion, both special-
ists agreed to participate in the study format as designed
below.
Materials and Methods
Between November 2011 and June 2012, all specimens from
the following surgical oncologic resections were prospective-
ly collected in the Leiden University Medical Center: esoph-
a g u s , s t om a c h ( p a r t i a l a n d t o t a l ) , p a n c r e a s
(pancreaticoduodenectomy according to Whipple), colon,
and rectum. Excluded were specimens which, after micro-
scopic evaluation, were diagnosed as benign or gastrointesti-
nal stromal tumors (GIST).
All patients underwent a potentially curative resection, and
all of them were preoperatively discussed in a multidisciplin-
ary team with radiologists, oncologists, radiotherapists, sur-
geons, and pathologists. In these weekly meetings, decisions
were made about the type of resection and, if relevant, (neo-)-
adjuvant treatment. Current protocol in the Leiden University
Medical Center (based on national guidelines) recommends
neo-adjuvant chemoradiation therapy (CRT) for esophageal
tumors, neo-adjuvant chemotherapy (CT) for gastric cancer,
and neo-adjuvant radiotherapy (RT) for T2–T4 rectal carcino-
mas. Neo-adjuvant therapy was renounced if a patient was
unfit for the recommended treatment. Surgical techniques
and protocols for (neo-)adjuvant treatment did not change
during the study period.
Every specimen was routinely evaluated by the pathologist.
This included a complete lymph node search of all the
resected tissue by the pathology resident after overnight for-
malin fixation and microscopic evaluation of the lymph nodes
by the resident and senior pathologist. During the study peri-
od, the mean time invested for this basic lymph node search
was 20 min per specimen. Consequently, during the same
week, a researcher (KdB) searched for additional lymph nodes
in the residual macroscopic tissue for exactly 20 min. The
number of potential lymph nodes retrieved was recorded ev-
ery 5 min by the researcher. These included additional lymph
nodes that were routinely processed and evaluated by the
resident and senior pathologist and reported in the final pa-
thology report. During the study period, mainly two pathology
residents examined the specimens. One resident was involved
from November until the end of December 2011 and the other
from January until June 2012. On occasion, another resident
pathologist substituted.
According to the Dutch rules for research for this study, no
approval from the ethics committee was deemed necessary as
only routine diagnostics were extended. Therefore, no in-
formed consent was obtained from patients. For the research-
er, all samples were handled in a coded fashion according to
National Ethical Guidelines.
In order to evaluate the number of lymph nodes found in
oncologic specimens in time, we retrospectively searched op-
eration files for operated patients and matched them by organ
and neo-adjuvant therapy to the prospective group.
Ultimately, retrospective group 1 consisted of surgical
specimens from which lymph node data were collected be-
tween January and December 2008. Retrospective group 2
consisted of surgical specimens retrospectively collected be-
tween September 2010 and November 2011. These periods
were deliberately chosen before and after 2009 because in that
year, minima were set for the number of lymph nodes dissect-
ed in colon and stomach resections to improve accurate stag-
ing (AJCC). In this manner, we could also evaluate the devel-
opment of lymph node counts under different protocols.
The database was statistically analyzed in SPSS (version
20). Numerical variables are summarized as mean (SD) or
range. The differences between the retrospective and prospec-
tive group characteristics (age and gender) were assessed
using the independent samples t test for age and chi-square
test for gender. Differences between groups with respect to
number of lymph nodes found were assessed using the inde-
pendent samples t test (comparisons between retrospective 1
and 2, between retrospective 2 and prospective A) and the
paired samples t test (comparison between prospective groups
A and B).
Results
The prospectively examined group consisted of a total of 67
oncologic specimens from patients operated in the Leiden
UniversityMedical Center. These specimens were categorized
by six different types of resections performed between
November 2011 and June 2012 (Table 1). The mean age of
the patients was 66.3 years, and 57 % of the patients were
male. The mean age and gender did not differ significantly
between the retrospective and prospective groups. As shown
in Table 1, 25 patients received neo-adjuvant therapy. Twelve
of them received neo-adjuvant chemoradiotherapy (CRT).
Eleven were diagnosed with esophageal cancer and one with
gastric cancer. The latter was preoperatively diagnosed as
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esophageal cancer, but after resection, the tumor proved to be
of gastric origin. Eleven patients with a gastric tumor received
neo-adjuvant chemotherapy (CT), and two patients with a
rectal tumor received neo-adjuvant radiotherapy (RT) (5×
5 Gy).
Tumor and node classification in this specimen cohort is
shown in Table 1. Most of the resected specimens were pT2 or
pT3 tumors (79.3%). Twenty-five patients were classified as a
pN0 tumor.
The mean number, standard deviation (SD), and range of
lymph nodes dissected for each type of specimen are shown in
Table 2. Lymph node count was significantly different be-
tween all groups. In retrospective group 1, before the protocol
with minimal number of lymph nodes to be retrieved was
implemented, fewer lymph nodes were collected (P=
<0.001). Finding none or one lymph node in an oncologic
specimen was reported more than once in this cohort. After
minima were set (retrospective group 2), significantly more
lymph nodes were evaluated (P=0.001) and no pathology
report includes less than five lymph nodes evaluated.
Table 3 shows the mean total lymph node count, the ma-
lignant lymph node count, and the percentage of malignant
lymph nodes. No significant differences were found in lymph
node counts between the 25 patients treated with neo-adjuvant
therapy and the 42 patients without neo-adjuvant therapy. The
mean lymph node count in the two patients who received neo-
adjuvant RT is lower compared to the other patients. These
patients had a rectal tumor, and mean lymph nodes dis-
sected for rectal specimens were overall lower in this
cohort (see Table 1).
The mean number of lymph nodes retrieved did not differ
between the levels of response to the given neo-adjuvant ther-
apy. Patients with a complete or a good response in this cohort
had no tumor-positive lymph nodes in the resected specimen.
pT4 tumors had a significant higher lymph node count
compared to the pT1–3 tumors. The percentage of malignant
lymph nodes in the specimens shows a gradual increase of the
amount of tumor-positive nodes when the tumor grows in size.
Table 1 Specimen characteristics
Esophagus (n=11) Partial gastric (n=10) Total gastric (n=8) Pancreas (n=25) Colon (n=9) Rectum (n=4) Total (n=67)
Neo-adjuvant treatment, n (%)
CT 0 (0 %) 5 (50 %) 6 (75 %) 0 (0 %) 0 (0 %) 0 (0 %) 11 (16.4 %)
RT 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %) 2 (50 %) 2 (3.0 %)
CRT 11 (100 %) 0 (0 %) 1 (12.5 %) 0 (0 %) 0 (0 %) 0 (0 %) 12 (17.9 %)
Tumor, n ( %)
T1 2 (18.2 %) 1 (10.0 %) 2 (25.0 %) 4 (15.4 %) 2 (22.2 %) 0 (0 %) 11 (16.4 %)
T2 6 (54.5 %) 1 (10.0 %) 3 (37.5 %) 5 (20.0 %) 0 (0 %) 2 (50.0 %) 17 (25.4 %)
T3 2 (18.2 %) 7 (70.0 %) 3 (37.5 %) 16 (64.0 %) 6 (66.7 %) 2 (50.0 %) 36 (53.7 %)
T4 1 (9.1 %) 1 (10.0 %) 0 (0 %) 0 (0 %) 1 (11.1 %) 0 (0 %) 3 (4.5 %)
Node, n (%)
N0 3 (27.3 %) 2 (20.0 %) 4 (50.0 %) 9 (36.0 %) 4 (44.4 %) 3 (75.0 %) 25 (32.8 %)
N1 6 (54.5 %) 4 (40.0 %) 2 (25.0 %) 16 (64.0 %) 4 (44.4 %) 1 (25.0 %) 33 (49.3 %)
N2 2 (18.2 %) 1 (10.0 %) 2 (25.0 %) 0 (0 %) 1 (11.1 %) 0 (0 %) 6 (9.0 %)
N3 0 (0 %) 3 (30.0 %) 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %) 3 (4.5 %)
Total, n (%) 11 10 8 25 9 4 67
Neo-adjuvant treatment: CT = chemotherapy, RT = radiotherapy, and CRT = chemotherapy and radiotherapy. Tumor and node according to TNM
classification of the different specimens. Resection: R0 complete resection, R1 microscopic incomplete resection and R2 macroscopic incomplete
resection
Table 2 Number of lymph nodes found per specimen and group
Retrospective 1 Retrospective 2 Prospective
Esophagus 11.3 [4.2] 14.3 [5.0] 24.1 [7.4]*
4–20 8–23 12–35
Partial gastric 10.3 [6.0] 18.4 [7.0]* 31.8 [9.2]*
0–18 8–28 18–42
Total gastric 17.6 [7.3] 14.9 [5.3] 27.1 [9.3]*
6–27 8–22 16–44
Pancreas 9.1 [5.5] 11.6 [3.7] 21.1 [7.1]*
0–20 6–21 9–36
Colon 12.9 [4.5] 17.3 [5.2]* 24.1 [5.9]*
5–19 11–28 14–31
Rectum 6.0 [5.0] 12.8 [5.9] 18.0 [6.4]
1–11 5–19 14–31
Total 10.9 [7.0] 14.3 [5.5]* 24.1 [8.3]*
0–27 5–28 9–44
Mean amount of lymph nodes found per group, [SD] and range
*P=<0.05, significant differences inmean lymph node count between the
groups and per specimen (an independent sample t test was used)
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Table 4 shows the number of patients diagnosed as N+ in
the retrospective groups and the prospective group. More pa-
tients were diagnosed as N+ in the prospective group (32 vs.
42, P=0.082). No difference was found between the two ret-
rospective groups. There is no clear correlation between
lymph node positivity (N+) and tumor origin.
To evaluate the amount of dissected lymph nodes within
the 20-min additive search, the cumulative mean number of
probable lymph nodes found per 5 min was calculated.
Adding 5- or 10-min search time increased the number of
retrieved lymph nodes by 12 and 20 %, respectively. Lymph
node retrieval decreased logarithmically in time. After 20min,
the cumulative mean number of extra lymph nodes retrieved
was 6; this accounted for 25% of the total number of dissected
lymph nodes.
Discussion
In this study, we found that when more time is invested in
lymph node search, significantly more lymph nodes can be
found in cancer resection specimens. Firstly, there is a clear
improvement in lymph node retrieval after minima for the
number of dissected lymph nodes per specimen were set in
2009. Secondly, we observed a significant difference between
numbers of lymph nodes retrieved in the retrospective group 2
(after these minima were set) and the number of lymph nodes
found in the prospective group. This leads to more patients
diagnosed as N+ in the prospective cohort compared to the
two retrospective cohorts; however, no significant difference
was found (P=0.082).
Other variables that may influence the number of lymph
nodes found are related to the surgeon and possible neo-
adjuvant therapy. If the surgical resection lacks sufficient lym-
phatic tissue, the pathologist will obtain fewer nodes. From
studies on more extended lymph node dissections, we know
that the surgical technique can make a great difference on the
number of lymph nodes found. For gastric cancer, this was
shown in a Dutch trial which showed an average of 17 lymph
nodes found after a limited (D1) dissection and an average of
30 lymph nodes found after an extended (D2) dissection.21 In
the current study, the same surgical resection techniques per
specimen were used for all patients. Therefore, the surgical
factor in the differences in lymph node retrieval found in this
study is considered limited.
Some studies have found substantial variability between
pathologists and the number of evaluated lymph nodes.
Ostadi et al.17 evaluated factors which contributed to a differ-
ence in lymph node count in colorectal specimens. They con-
cluded that most variation was accounted for by differences
between pathologists. Evans et al.18 found no differences in
lymph node harvest in colorectal cancer between individual
surgeons but did find that there was a significant difference
between reporting pathologists. Kuiper et al.19 reported that
their laboratory technicians retrieved more lymph nodes than
the pathologists, and Mekenkamp et al.20 found large differ-
ences in lymph node retrieval between various pathologists
and between different laboratories. Based on the current study
and the four studies cited above, it appears that the time
invested in lymph node retrieval is the most crucial factor
for adequate lymph node retrieval.17
–20












Nil (n=42) 23.0 4.5 19.6
CT (n=10) 30.8 3.6 11.7
RT (n=2) 19.5 1.0 5.1





No response (n=3) 25.7 1.7 6.6
Partial (n=19) 26.1 3.6 13.8
Good/complete (n=3) 25.7 0
Tumor
T1 (n=11) 23.4 1.2 5.1
T2 (n=17) 24.3 2.8 11.5
T3 (n=36) 23.7 4.7 19.8
T4 (n=3) 30.0 11.0 36.7
Node
N0 (n=25) 24.1 0 0
N1 (n=33) 23.6 4.0 16.9
N2 (n=6) 23.8 8.0 33.6
N3 (n=3) 29.7 25.0 84.2
Total (n=67) 24.1 3.8 15.8
Neo-adjuvant treatment: CT = chemotherapy, RT = radiotherapy, and
CRT = chemotherapy and radiotherapy. Tumor and node according to
TNM classification of the different specimens. Resection: R0 complete
resection, R1 microscopic incomplete resection, and R2 macroscopic
incomplete resection
Table 4 Differences in N status of the TNM classification in the study
groups
Retrospective 1 Retrospective 2 Prospective
N0 35 (52.2 %) 35 (52.2 %) 25 (37.3 %)
N+ 32 (47.8 %) 32 (47.8 %) 42 (62.7 %)
Total 67 (100 %) 67 (100 %) 67 (100 %)
In Table 3, the amounts and percentages of total patients diagnosed with
pN0 or pN+ per group are shown.More patients were diagnosed as N+ in
the prospective group, and this was not significant (P=0.082)
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From the pathologist’s point of view, there is a consensus
that neo-adjuvant CRT may result in the retrieval of fewer
lymph nodes, especially when conventional manual lymph
node dissections are used.20
,22 Mekenkamp et al.20 showed
that after neo-adjuvant RT, fewer lymph nodes were retrieved
in rectum specimens (6.9 vs. 8.5; P<0.0001). In esophageal
cancer, the same effect of CRT to lymph node retrieval has
been shown (6.9 vs. 8.6; P=0.026).23 RT is thought to de-
crease lymph node yield as a result of an immune response,
rendering them undetectable because of RT-induced fibrosis.
The shrinkage after RT makes lymph node retrieval more
challenging. Nevertheless, in the above-mentioned studies,
lymph node metastasis (and micro-metastasis) has been found
in lymph nodes <0.3 cm. Thereby suggesting that, although
lymph node evaluation is more challenging, it is crucial for
accurate staging.24
–26 In our study, there was no significant
difference in lymph node counts between specimens treated
with or without neo-adjuvant (C)RT. However, the groups
were too small for accurate statistic analysis.
In order to facilitate large amounts of lymph node recovery,
fat clearance techniques have been developed. Average lymph
node counts over 50 have been reported when using these
techniques. However, fat clearance techniques are not often
used because they are time-consuming (1 to 5 weeks extra per
specimen) and more expensive.25
,26
Comparing the number of patients diagnosed as pN+ in our
three groups shows an interesting result. The adjustment of
guidelines did lead to an increased number of lymph nodes
evaluated, but not to a change in percent of patients staged
with pN+ disease. In the prospective group, however, we ob-
served a clear stage migration since more patients were diag-
nosed as pN+ compared to the retrospective groups (62.7 vs.
47.8 %, respectively, P=0.082). The more extensive search in
the prospective groups may have led to this stage migration
phenomenon.
The estimated average search time for lymph node retrieval
by the pathology resident was approximately 20 min. The
time for reexamination for additional lymph nodes was set at
20 min as a longer search seemed unfeasible for routine path-
ological practice. In the additional search, the largest number
of extra lymph nodes was found during the first 5 min, and this
number decreased logarithmically in time. Adding 5- or 10-
min search time increased the number of retrieved lymph
nodes by 12 and 20 %, respectively. Although data are insuf-
ficient to make firm conclusions, considering the estimated
search time by the pathology resident, the optimal total time
for lymph node retrieval may be around 30 min, although this
may differ between oncologic specimens and origin, depend-
ing on the amount of fatty tissue.
There are some limitations to our study. Firstly, the number
of extra lymph nodes found by the researcher was registered
every 5 min, but the initial lymph node search by the pathol-
ogy resident was not recorded in detail. Secondly, no data was
collected on the outcome and the possible change in adjuvant
treatment and prognosis. For certain tumor types, like pancre-
as carcinomas, the “stage migration” due to the extra dissected
lymph nodes would not lead to a change in postoperative
management. However, it will make a difference in prognosis,
and therefore, it will still be relevant for the patient. For other
tumor types, like colon cancer, it may alter adjuvant treatment.
Finally, the data from the two retrospective groups was
collected via the electronic database of the hospital. This has
its obvious retrospective data collection hazards, and for our
study, specifically, there was no indication of the total time
invested in lymph node search.
Conclusion
Significantly more lymph nodes can be found in oncologic
specimens when more time for searching is invested. This will
improve accurate staging of the patients and could have im-
portant implications for (adjuvant) therapy and prognosis. The
optimal time for retrieval of lymph nodes may be around
30 min, and the surplus value of retrieving decreases in time.
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